Iambic reports Q3 2026 results, new HER2 data and planned 2027 registrational trial
Iambic highlighted updated IAM1363 data at ESMO, a new IAM217 Safe-to-Proceed letter, and a pro forma cash position of about $455 million after its October IPO.
Drugs@FDA, FDA, SEC filing (3)